Ageo, Japan

Hidefumi Matsui


Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Ageo, JA (1976)
  • Kitamoto, JP (1979)

Company Filing History:


Years Active: 1976-1979

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Hidefumi Matsui

Introduction

Hidefumi Matsui is a notable inventor based in Ageo, Japan. He has made significant contributions to the field of pharmaceuticals, holding 2 patents that showcase his innovative approach to drug formulation.

Latest Patents

Matsui's latest patents include a pharmaceutical composition of a prostaglandin compound for rectal use. This composition contains 11.alpha.,15(S)-dihydroxy-20-methoxy-16(S)-methyl-9-oxo-5(cis,13(trans)-prostadienoic acid or a water-soluble salt thereof, dissolved or dispersed in a lipophilic or hydrophilic base. It can be used in the presence or absence of a buffer solution or an aqueous organic amine solution. Another significant patent is for novel oxofuryl ester derivatives of penicillin and cephalosporin. These derivatives are represented by a specific general formula and are designed to be readily absorbed by the intestines, demonstrating antibacterial activity while minimizing toxicity compared to known compounds.

Career Highlights

Matsui is associated with Yamanouchi Pharmaceutical Company Ltd., where he has been instrumental in advancing pharmaceutical research and development. His work focuses on creating effective and safer drug formulations that can improve patient outcomes.

Collaborations

Matsui has collaborated with notable coworkers, including Kenichi Tomioka and Hiroitsu Kawada. Their combined expertise has contributed to the success of various projects within the pharmaceutical sector.

Conclusion

Hidefumi Matsui's innovative contributions to pharmaceutical compositions highlight his commitment to improving healthcare through effective drug development. His patents reflect a deep understanding of medicinal chemistry and a dedication to enhancing therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…